Jiangsu Aidea Pharmaceutical Co.Ltd(688488)
List of incentive objects first granted by restricted stock incentive plan in 2022
The distribution of restricted shares first granted by the company’s restricted stock incentive plan in 2022 among incentive objects is as follows:
Proportion of granted restrictions to the total share capital (10000 shares) at the time of announcement
1 Fu Heliang, chairman and President of China, 60.00 8.08% 0.14%
Chief executive officer
2 Zhang Jing, senior vice president of China 50.00 6.73% 0.12%
3 Hong Qi senior vice president of the UK, first 30.00 4.04% 0.07%
Xi Technical Officer
Xiaoning director, vice president
4 Christopher US chief scientific officer 30.00 4.04% 0.07%
Sheng
5 Wu Rongrong, vice president and chief physician of China 30.00 4.04% 0.07%
Academic officer
6 Wang Jun, director and vice president of China, 30.00 4.04% 0.07%
chief operating officer
7 Yu Ke, director and vice president of China, 30.00 4.04% 0.07%
Chief financial officer
8 Wang Guangrong, Secretary of the board of directors and deputy director of China 30.00 4.04% 0.07%
CEO
Core technology (business) backbone personnel (67 persons) 304.50 41.01% 0.73%
Reserved part 148.00 19.93% 0.35%
Total 742.50 100.00% 1.77%
Note:
1. The shares of the company granted by any of the above incentive objects through all the equity incentive plans within the validity period shall not exceed 1% of the total share capital of the company. The total number of underlying shares involved in the incentive plan within the whole validity period of the company shall not exceed 20% of the total share capital of the company when the equity incentive plan is submitted to the general meeting of shareholders for deliberation. The proportion of reserved rights and interests shall not exceed 20.00% of the number of rights and interests to be granted in the incentive plan.
2. The incentive objects of the plan do not include independent directors and supervisors.
3. The incentive objects of the reserved part shall be determined within 12 months after the incentive plan is considered and approved by the general meeting of shareholders. After the proposal of the board of directors, the explicit opinions of the independent directors and the board of supervisors, the professional opinions of lawyers and the legal opinions are issued, the company shall timely and accurately disclose relevant information on the designated website as required.
4. If the total number in the above table is inconsistent with the mantissa of the sum of the sub item values, it is caused by rounding.
Jiangsu Aidea Pharmaceutical Co.Ltd(688488) board of directors January 19, 2022
